Description

The recombinant human IL-7-Fc fusion protein is a glycosylated functional dimer produced in CHO expression systems, engineered with a C-terminal human IgG1 Fc domain to enhance protein stability and receptor clustering efficacy.

As a pivotal member of the IL-2 cytokine family, IL-7 activates the JAK1/JAK3-STAT5 signaling cascade via its heterodimeric receptor (IL-7Rα/γc), driving survival, proliferation, and differentiation of T/B/NK cells while maintaining lymphocyte homeostasis through Bcl-2-mediated anti-apoptotic mechanisms and promoting CD4+/CD8+ double-positive T-cell maturation during thymic development.

In cell therapy manufacturing, this fusion protein serves as a critical culture additive to enhance CAR-T cell metabolic fitness and memory phenotype formation through sustained PI3K-AKT-mTOR pathway activation. It synergizes with IL-15 to suppress exhaustion markers (e.g., PD-1/TIM-3) while supporting hematopoietic stem cell differentiation into functional lymphoid progenitors, thereby improving the persistence and antitumor efficacy of adoptive immune cell products.

The Fc-mediated dimeric configuration mimics native membrane-bound IL-7 bioactivity and optimizes pharmacokinetic profiles through extended serum half-life.

Specifications

Cytokines Details
Synonyms	Interleukin-7, IL-7
Accession	UniProt P13232-1
Expressed Region	Asp26–His177
Fusion Tag	Human IgG1 Fc fragment fused to the C-terminus
Expression System	CHO cells
Predicted Molecular Weight	43.8 kDa
Purity	> 95% as determined by SDS-PAGE and HPLC
Endotoxin	< 0.01 EU per 1 μg of protein (LAL method)
Biological Activity	Exhibits dose-dependent proliferation of PHA-activated PBMCs with an ED₅₀ of 0.5–20 ng/mL and a specific activity > 1.0 × 10⁷ IU/mg
Formulation	Lyophilized from sterile 20 mM phosphate-buffered saline (PBS), pH 7.4, typically containing 6–8% (w/v) mannitol as a stabilizing protectant

Features

✔ High Biological Activity
Potently drives lymphocyte proliferation via IL-7Rα/γc–STAT5 signaling, validated by PBMC assays.
✔ Fc-Fusion Dimeric Design
Human IgG1 Fc fusion enhances protein stability, receptor clustering, and functional persistence.
✔ Excellent Batch Stability
GMP-compliant manufacturing ensures consistent purity, activity, and ultra-low endotoxin levels.
✔ DMF Filed (038126)
Supports regulatory readiness for cell and gene therapy development.

Applications

T Cell Expansion and Memory Formation

Enhances survival, metabolic fitness, and memory phenotype in CAR-T and T-cell cultures.

NK Cell Activation and Maintenance

Promotes NK cell proliferation and functional persistence in immunotherapy workflows.

Cell and Gene Therapy Manufacturing

Ideal as a cytokine supplement in GMP-aligned immune cell production processes.

Advanced Immunology Research

Suitable for studies requiring sustained IL-7 signaling and lymphocyte homeostasis control.

Data Figures

Stability & Storage

Lyophilized powder: Stable for 12 months at -80°C or 6 months at -20°C when stored inthe original sealed container under desiccant.
Reconstitution: Dissolve in sterile Water for Injection, 0.9% NaCl, or PBS (pH 7.4)maintaining final concentration ≥100 µg/mL to prevent adsorption.
Handling: Aliquot to avoid repeated freeze-thaw cycles.

Cautions

• Research Use Only: This product is not intended for diagnostic or therapeutic use.

• Handling: Follow recommended storage and handling instructions to maintain product stability.

• Support: Contact technical support if assistance is required.

Documents

📄 GMP-TL506 SDS 📄 GMP-TL506 Data Sheet 📄 GMP-TL506-0050 COA 📄 GMP-TL506-0100 COA

Recombinant Human IL-7 Protein